Augmentine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Augmentine

Property Description
Active ingredients Amoxicillin, Clavulanic acid
Form Tablets, Oral Suspension
Pharmacological class Penicillins/beta-Lactamase Inhibitors
Common use Treatment of bacterial infections
Origin Semisynthetic

What Type of Medicine is Augmentine?

The medicine known by the International Nonproprietary Name (INN) Amoxicillin and Clavulanic acid combination is a semisynthetic oral antibacterial medicine used to treat infections caused by susceptible bacteria. This combination product is classified as a member of the Penicillins/beta-Lactamase Inhibitors drug class and is defined as a fixed dosage combination product. This structure is a key feature that is clinically recognized for successfully addressing resistance often encountered with single-agent penicillins.

Composition: Why Does Augmentine Combine Two Active Ingredients?

Augmentine is composed of two active ingredients: Amoxicillin (a penicillin-class antibacterial) and Clavulanic acid (a beta-Lactamase inhibitor, typically formulated as its potassium salt). The strategic inclusion of Clavulanic acid is crucial for overcoming bacterial drug resistance mechanisms. The addition of clavulanic acid ensures that the amoxicillin can effectively act on bacteria that are resistant to amoxicillin alone. This dual composition is supported by extensive pharmacological studies and ensures a more robust general approach to managing susceptible bacterial infections, such as those affecting the respiratory tract or the skin. The formulation is also commonly known under other commercial names, including Co-amoxiclav or Clavulin.

Available Forms of Augmentine

The medicine is supplied in various pharmaceutical preparations for the oral route of administration to suit patient needs. These forms typically include film-coated tablets, chewable tablets, and powder for oral suspension. This allows for the precise delivery of the active components to both adult and pediatric patients. Furthermore, this medication is widely recognized as an essential medicine, underscoring its therapeutic importance in global health systems.

Regulatory References

  1. Amoxicillin and Clavulanic Acid Drug Information

What side effects are possible with Augmentine?

Possible Side Effects and Safety Information

The safety profile of Augmentine (amoxicillin/clavulanic acid) is established through regulatory classification of adverse reactions based on frequency and affected body systems, as documented by governmental authorities.

Adverse Reactions by Frequency

Adverse reactions are organized by how frequently they are reported:

  • Very Common / Common: Expected reactions include diarrhea, nausea, vomiting, and skin rashes (urticaria). Diarrhea is typically the most frequently reported side effect.
  • Rare: Rare events include severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS).
  • Unknown Frequency: Events reported from post-marketing experience with frequency that cannot be reliably estimated include Drug-Induced Enterocolitis Syndrome (DIES), Kounis syndrome, and amoxicillin crystalluria.

Serious Adverse Reactions and Systemic Effects

Adverse effects are categorized by the System-Organ-Class (SOC) they affect. Clinically significant reactions include:

  • Hepatobiliary Disorders: Serious, and rarely fatal, liver problems such as cholestatic jaundice and hepatitis have been documented. These may occur during or several weeks after treatment.
  • Immune System Disorders: Serious hypersensitivity reactions, including anaphylaxis and angioedema, are a recognized risk.
  • Gastrointestinal Disorders: Severe colitis caused by Clostridioides difficile (CDAD) is a serious, life-threatening complication.

Safety Restrictions and Limitations

Augmentine is contraindicated in patients with a history of serious allergic reaction (e.g., anaphylaxis) to any penicillin or cephalosporin, or a prior history of liver dysfunction (cholestatic jaundice/hepatitis) associated with the drug. Additionally, caution is required, and use may be contraindicated, in patients with infectious mononucleosis or pre-existing severe renal impairment.

Overdose and Emergency Response

The official regulatory profile for Augmentine (amoxicillin and clavulanic acid) overdose documents the expected clinical presentations and mandatory emergency actions. Overdose is primarily associated with gastrointestinal distress, including severe nausea, vomiting, and diarrhea. At high exposure levels, Central Nervous System (CNS) effects such as convulsions (seizures), hyperactivity, and drowsiness have been documented.

Documented Risks and Complications

The most serious outcome is the potential for Amoxicillin Crystalluria, which may obstruct the renal tubules and lead to acute renal injury. Severe hepatic events have also been noted in rare circumstances. Patients with impaired renal function are identified as being at increased risk for CNS effects and crystalluria complications.

Official Emergency Management

Because no specific antidote is known, management is officially defined as symptomatic and supportive treatment. Procedural steps documented for reducing exposure include gastric lavage and the administration of activated charcoal. Hemodialysis is documented as a means to effectively remove both active components from the system. In all cases of suspected overdose, regulatory information mandates that individuals seek immediate medical attention. The medication must be discontinued immediately if a severe hypersensitivity reaction occurs.

Therapeutic Uses of Augmentine

Augmentin (amoxicillin and clavulanate potassium) is a therapeutic agent used in situations involving certain distressing symptoms. It is commonly used to help with conditions characterized by periods of heightened symptoms that interfere with daily functioning. This combination medicine is applied across therapeutic domains including the ears, lungs, sinus, skin, and urinary tract. This medicine is considered relevant when supportive symptom management is appropriate, and is applied across domains where additional symptomatic support is needed.


Therapeutic Focus: Managing Symptom Clusters

This agent is relevant for managing symptoms that interfere with daily comfort, such as those linked to conditions like sinusitis, acute otitis media, lower respiratory tract infections (including certain types of pneumonia), urinary tract infections (UTIs), and skin and soft tissue infections. It is applied during phases of increased distress or discomfort.


Symptomatic Relief and Stability

When symptoms become temporarily overwhelming, this medicine may assist with maintaining functional stability and helps maintain a sense of stability when symptoms are more noticeable. It is applicable within clinical settings that involve acute or disruptive symptom patterns, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Physiological Strain

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Augmentine

Populations for whom use is contraindicated:

  • Patients with a history of serious hypersensitivity (e.g., anaphylaxis) to Augmentine or any other beta-lactam antibacterial drugs (penicillins or cephalosporins).
  • Patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior Augmentine treatment.

Age-related eligibility rules:

  • Use is established for adults and pediatric patients generally ge 12 weeks (3 months).
  • The 875-mg strength tablet is prohibited for children and adolescents.

Condition-specific eligibility rules:

  • Severe Renal Impairment (creatinine clearance < 30 mL/min): The 875-mg tablet is prohibited; other formulations require dose adjustment.
  • Hepatic Impairment: Must be administered with caution and requires regular function monitoring.
  • Infectious Mononucleosis: Use must be avoided due to the associated risk of developing a morbilliform skin rash.
  • Phenylketonuria (PKU): Certain oral suspension and chewable tablet formulations containing aspartame are prohibited.

Pregnancy and lactation eligibility status:

  • Pregnancy: Permitted only if clearly needed (FDA Category B). Avoided for prophylaxis in women with premature rupture of membranes.
  • Lactation: Use requires caution as amoxicillin is excreted in human milk, carrying the potential for infant sensitization.

Connection to the overall eligibility profile: Official regulatory documents strictly define eligibility through absolute prohibitions and conditional requirements. Non-eligibility is determined by a history of severe allergic reaction or prior drug-associated liver damage. Use is restricted across various populations, specifically due to severe organ impairment and condition-specific risks, requiring explicit monitoring or formulation avoidance.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Amoxicillin and Clavulanic acid is strictly documented by regulatory authorities, focusing on changes to systemic exposure and specific pharmacodynamic effects.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Official Interaction Statement Constraint
Probenecid Reduces the renal tubular secretion of amoxicillin, resulting in increased and prolonged plasma concentrations of amoxicillin. Co-administration is not recommended.
Methotrexate May reduce the excretion of methotrexate, potentially increasing its toxicity and exposure. Relevant consideration for patients with impaired renal function.
Oral Anticoagulants (e.g., Warfarin) May lead to an abnormal prolongation of Prothrombin Time (INR). Requires close monitoring of INR.
Allopurinol Increases the incidence of skin rashes when co-administered with amoxicillin. Not a formal contraindication, but an increased risk is documented.
Oral Contraceptives May reduce the efficacy of combined oral estrogen/progesterone contraceptives. Risk is noted in regulatory documents.

Food and Laboratory Test Interactions

Administration at the start of a meal is advised to optimize the absorption of the clavulanic acid component and help minimize potential gastrointestinal intolerance. The medicine can interfere with certain medical laboratory results, potentially causing false-positive direct Coombs tests and false-positive results when using non-enzymatic methods for urine glucose testing.

Mechanism of Action

Augmentine is a nitrogen-containing bisphosphonate that acts by selectively binding to the mineral matrix of bone tissue, particularly at sites of high turnover. Following incorporation into the matrix, the compound is specifically internalized by active osteoclasts during the process of bone resorption.

Within the osteoclast, Augmentine acts as a non-hydrolyzable analog of pyrophosphate, interfering with the farnesyl pyrophosphate synthase (FPPS) enzyme in the mevalonate pathway. Inhibition of FPPS prevents the prenylation of small guanosine triphosphate (GTP)-binding proteins, leading to a disruption of the osteoclast cytoskeleton and the loss of the ruffled border. This cascade induces apoptosis (programmed cell death) in the osteoclast. The resulting physiological modulation is the direct inhibition of osteoclast-mediated bone resorption, thereby decreasing the overall rate of bone remodeling.

Dosage and Administration Information

How to Use Augmentine

This section outlines the general principles and administration guidelines for Amoxicillin and Clavulanic acid.


Administration Scope

Feature Official Labeled Guideline
Route of Administration Primarily Oral (Tablets, Suspension) for outpatient use; Intravenous administration is approved for certain severe infections in the inpatient setting.
Timing in Relation to Meals Dosing must occur at the start of a meal to enhance the absorption of the clavulanic acid component and minimize potential gastrointestinal discomfort.
Dosing Frequency Regimens utilize divided daily doses, typically administered every 12 hours (q12h) for high-dose forms (e.g., 875 mg or Extended-Release) or every 8 hours (q8h) for standard formulations, depending on the specific strength prescribed.
Treatment Duration Limit Therapy should not be extended beyond 14 days without careful clinical reassessment.

Procedural and Population-Specific Instructions

Administration requires adherence to specific procedures based on the pharmaceutical form. Extended-Release (ER) tablets must be swallowed whole and cannot be crushed or chewed, and standard tablets of different strengths are generally not interchangeable. The powder for Oral Suspension requires reconstitution with water and must be shaken well prior to administration. For pediatric patients weighing under 40 kg, the dosage is determined based on the child's body weight (mg/kg/day of the amoxicillin component). Dose adjustment is mandatory for adults with moderate-to-severe renal impairment (creatinine clearance <30 mL/min), and the highest-strength tablets are not recommended for this group.

Recent Clinical Evidence

Research evidence / Overview of studies

Research regarding the drug, a combination of amoxicillin and clavulanic acid, has focused on its role in treating bacterial infections, particularly those caused by bacteria that produce resistance enzymes. The available findings describe study outcomes and are not clinical recommendations. Individuals are encouraged to discuss their health needs with a healthcare professional for personalized guidance.

Studies on Drug Activity

Research has explored the drug's activity, noting that the clavulanic acid component protects the amoxicillin from degradation by certain bacterial enzymes (beta-lactamases), effectively broadening the spectrum of bacteria susceptible to the drug. This protective action is a key focus of ongoing pharmacological studies.

Phase II and III Clinical Trials

Clinical trials have assessed the drug's potential in localized symptom management across various patient populations, including those with respiratory and ear infections. The trials utilize defined treatment protocols over periods such as 7 to 14 days.

Findings on Efficacy and Safety

Clinical data from a systematic review of randomized, placebo-controlled trials suggest that when compared to placebo for treating certain infections, the combined treatment is generally associated with a higher rate of diarrhea. The number needed to harm (NNH) for diarrhea due to amoxicillin–clavulanic acid was approximately 10. Other reported adverse events were generally not significantly increased.

Specific trials focused on children with acute otitis media (AOM) or patients with lower respiratory tract infections (LRTIs). In an observational study concerning LRTIs, clinical recovery was achieved in a high percentage of patients (around 95%) receiving the drug. However, factors like chronic cough or chronic dyspnea were observed to potentially hinder clinical recovery in some patients. Further high-quality randomized, controlled trials are continually being conducted to establish long-term safety profiles and efficacy across different infectious diseases and bacterial resistance patterns.

Frequently Asked Questions (FAQ)

Common questions about Augmentine (FAQ)

Q: How quickly does Augmentine start working to fight an infection?

A: According to official clinical pharmacology data, the maximum concentration of the drug's active components in the bloodstream generally occurs about one hour after you take an oral dose. The half-life, which indicates how long the medicine stays in the system, is relatively short, which is why it is prescribed in divided daily doses. This presence in the bloodstream indicates when the active components are most present in the bloodstream.


Q: Is it possible to have a yeast infection (thrush) after taking Augmentine?

A: Yes, mucocutaneous candidiasis, which is a yeast or fungal infection like thrush, is listed as a common adverse reaction in official product information. Like other antibacterial medicines, Augmentine can alter the natural balance of bacteria and fungi in the body. If this occurs, it is generally considered a superinfection.


Q: Is Augmentine safe to use during pregnancy, and what is its classification?

A: Augmentine is classified by the FDA as Pregnancy Category B, meaning animal reproduction studies have generally not demonstrated a risk to the fetus. Official documents state that it should be used during pregnancy only if a healthcare provider clearly determines it is needed. It is typically avoided in a preventative context for women with premature rupture of membranes.


Q: Does Augmentine pass into breast milk during breastfeeding?

A: Yes, the amoxicillin component of the medicine is excreted into human milk. Regulatory documents state that use requires caution because this may lead to potential effects in the nursing infant, such as sensitization (developing an allergy), diarrhea, or a rash.


Q: How can Augmentine interact with oral birth control pills?

A: Official product information notes that Augmentine may potentially reduce the effectiveness of combined oral contraceptives that contain estrogen and progesterone. This information highlights a potential risk that patients should be aware of when taking both medicines.


Q: Is Augmentine appropriate for use in children?

A: Use is established for pediatric patients generally 12 weeks of age and older. Pediatric dosing is based on the child's body weight to ensure appropriate treatment levels. However, it is officially prohibited to use the highest 875 mg strength tablet in children and adolescents.


Q: Are there specific storage instructions for the liquid form of Augmentine?

A: The oral suspension is supplied as a powder that requires mixing with water (reconstitution) before use. Once reconstituted, the liquid must be stored in a refrigerator, kept between 2 C and 8 C, and should not be frozen. It is only stable for 10 days and must be safely discarded after that period.


Q: Can taking Augmentine cause dizziness or affect my ability to drive?

A: Dizziness has been reported, although rarely, as a central nervous system-related adverse reaction. While official product information lists this potential side effect, it does not provide explicit direction regarding the ability to drive. Consultation with a healthcare provider can offer personalized guidance on this matter.


Q: What happens if I forget to take a dose of Augmentine?

A: Official patient information often describes that a missed dose may be taken as soon as it is remembered, unless it is almost time for the next dose, in which case the missed dose is skipped entirely. It is stated that a double dose should not be taken to compensate for a missed dose.


Q: What types of infections is Augmentine most commonly prescribed for?

A: According to the FDA and EMA indications, Augmentine is indicated for treating bacterial infections in various parts of the body. These commonly include lower respiratory tract infections, acute bacterial otitis media (ear infections), sinusitis, skin and skin structure infections, and urinary tract infections.


Q: Is Augmentine considered a broad-spectrum antibiotic?

A: Yes, the official formulation is generally described in pharmacological literature as possessing the properties of a broad-spectrum antibiotic. This is because the clavulanic acid component protects the amoxicillin from being broken down by resistance enzymes (beta-lactamases), allowing it to target a wider range of bacteria.


Q: Is it normal to feel tired or fatigued while taking Augmentine?

A: Official adverse reaction lists do not categorize fatigue as a common expected reaction. Fatigue or unusual weakness are sometimes associated with liver injury, which is a rare but severe adverse effect listed in the official safety information.


Q: Can Augmentine cause a fever as a side effect?

A: Fever is not listed as a frequently reported adverse reaction to the drug itself. However, a fever can be a warning sign of a severe event, such as a serious allergic reaction or the rare, severe intestinal infection known as Clostridioides difficile-associated diarrhea (CDAD).


Q: Can Augmentine cause a skin rash, and when should I be concerned?

A: Skin rashes, such as urticaria (hives), are listed as a common adverse reaction. Official safety information indicates concern is warranted if the rash progresses rapidly or is accompanied by other symptoms like fever or flu-like illness. These combinations are indicators of a serious skin reaction documented in the safety profile.


Q: Is there a link between Augmentine and black hairy tongue?

A: Yes, 'black hairy tongue,' or tongue discoloration, has been reported as a rare adverse reaction in post-marketing experience with the medicine. This is typically a temporary condition.


Q: Can Augmentine cause difficulty sleeping or increased anxiety?

A: Difficulty sleeping (insomnia) and feelings of anxiety have been reported as central nervous system-related adverse reactions in the official prescribing information. These effects are reported rarely.


Q: Is it true that Augmentine should not be used for viral infections like a cold or flu?

A: Yes, official prescribing information explicitly states that Augmentine should only be used to treat infections that are proven or strongly suspected to be caused by bacteria. The medicine is not effective against viral illnesses such as the common cold or influenza.


Q: Are there any specific foods or drinks that should be avoided while taking Augmentine?

A: The official label does not list any specific food or drink that must be avoided, but general administration advice is provided. To minimize potential gastrointestinal intolerance and help with absorption, it is advised to take the medicine at the start of a meal.


Q: Does the higher strength of Augmentine (875 mg) cause more side effects than lower doses?

A: Clinical studies reviewed in the FDA label have noted that the higher-strength regimen, which is often associated with the 875 mg tablet taken every 12 hours, is associated with significantly less diarrhea compared to the standard every 8 hour regimens.


Q: Does Augmentine have a risk of causing kidney stones or crystalluria?

A: Amoxicillin crystalluria, which is the presence of crystals in the urine, has been reported in post-marketing experience with an unknown frequency. Official information indicates that this is a recognized adverse event associated with the drug.


Q: What is the known evidence regarding Augmentine's use in dental infections?

A: Augmentine is officially indicated for the treatment of various bacterial infections, including skin and skin structure infections. While dental infections are not listed as a specific primary indication, the medicine's general indications may cover some types of infection that occur in the dental context.


Q: Does Augmentine affect blood clotting time?

A: The official label states that when Augmentine is taken at the same time as oral anticoagulants (blood thinners like Warfarin), it may lead to an abnormal prolongation of the Prothrombin Time (INR). The official label does not address the general effect on clotting time in patients not using blood thinners.


Q: What is known about Augmentine's effectiveness in patients with mononucleosis?

A: The effectiveness of Augmentine for the underlying mononucleosis infection is not discussed in the label. Instead, official prescribing information strictly states that the use of Augmentine must be avoided in patients with infectious mononucleosis due to the high risk of developing a generalized skin rash.


Q: Have there been any major studies on the long-term effects of Augmentine?

A: Regulatory documents state that therapy should not be extended beyond 14 days without a careful clinical reassessment by a healthcare professional. Therefore, the studies detailed in the product label typically focus on the treatment periods of 7 to 14 days and not on extended or long-term use.


Q: What are the guidelines regarding alcohol consumption while taking Augmentine?

A: There is no known direct or dangerous interaction between Augmentine and alcohol listed in the official documents. However, general patient information cautions that consuming alcohol may potentially increase or worsen common side effects of the medicine, such as nausea, vomiting, or headache.


Q: Does Augmentine increase the risk of developing joint or muscle pain?

A: Arthralgia, which is joint pain, is listed in the official safety profile as a rare symptom. This joint pain is associated with severe hypersensitivity reactions, such as serum sickness-like reactions, rather than being a common expected effect.

How should Augmentine be stored and disposed of?

Storage and Disposal of Augmentin (Amoxicillin and Clavulanate Potassium)

The official storage conditions for Augmentin differ by formulation to ensure stability.

Storage Requirements

Formulation Required Storage Condition
Tablets and Dry Powder Store at Controlled Room Temperature (20 C to 25 C). Keep in the original, tightly closed container to protect from moisture.
Reconstituted Suspension Must be stored in a refrigerator (2 C to 8 C) and must not be frozen.

The reconstituted suspension has a 10-day stability limit and must be discarded after that period. All forms must be kept out of the sight and reach of children.

Disposal

Expired or unused medicine must be disposed of safely. Disposal must be performed in accordance with local requirements and official guidelines for discarding medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Augmentine found in:

A-Z Index: